Tbp Protein Tata Box Binding Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
TBP (TATA-Box Binding Protein) is a general transcription factor that initiates RNA polymerase II transcription by binding to the TATA box promoter element. It is encoded by the TBP gene located on chromosome 6q27 and is essential for eukaryotic transcription.
| TBP Protein |
|---|
| Protein Name | TATA-Box Binding Protein |
| Gene | TBP |
| UniProt ID | P20226 |
| Molecular Weight | 38 kDa |
| Subcellular Localization | Nucleus |
| Protein Family | TBP family |
TBP has a saddle-shaped structure:
- C-terminal core: Composed of two repeats of 180 amino acids each
- N-terminal region: Glutamine-rich, involved in transcriptional activation
- DNA-binding surface: Curved β-sheet that inserts into the major groove of DNA
TBP is the core component of TFIID:
- Binds to TATA box sequence (TATAAA)
- Recruits TFIIA, TFIIB, and other general transcription factors
- Positions RNA polymerase II at the transcription start site
- Functions in both basal and activated transcription[1]
- Mediates transcriptional activation by transcription factors
- Involved in TATA-less promoter recognition
- Participates in RNA polymerase I and III transcription
In AD, TBP is affected by:
- Transcriptional dysregulation: Global downregulation of transcription in AD brain[2]
- Tau pathology: TBP is found in neurofibrillary tangles
- Epigenetic changes: Altered TBP binding in AD
- Transcriptional dysfunction is a hallmark of HD
- TBP is recruited to mutant huntingtin aggregates
- TBP levels altered in HD models and brain[3]
TBP polyglutamine expansions cause:
- SCA17 (autosomal dominant cerebellar ataxia)
- TBP aggregates in affected neurons
- Transcriptional repression
| Approach |
Mechanism |
Status |
| Transcriptional activators |
Restore gene expression |
Research |
| Histone deacetylase inhibitors |
Epigenetic therapy |
Clinical trials |
| Aggregate clearance |
Remove TBP aggregates |
Research |
| Disease |
Role |
Evidence |
| Alzheimer's Disease |
Transcriptional dysregulation |
Altered TBP in AD[2] |
| Huntington's Disease |
Transcriptional dysfunction |
TBP in mHTT aggregates[3] |
| SCA17 |
Genetic cause |
Polyglutamine expansion |
| Parkinson's Disease |
Transcriptional changes |
Altered TBP levels |
[1] Lee TI, Young RA. Transcription of eukaryotic protein-coding genes. Annu Rev Genet. 2000.
[2] Lu T, et al. Gene expression and regulation in AD. Neurobiol Aging. 2004.
[3] Shimohata T, et al. TBP in Huntington's disease. Nat Neurosci. 2000.
TBP is essential for transcription by all three eukaryotic RNA polymerases:
- Pol I: TBP-L (TBP-like factor) replaces TBP for rRNA transcription
- Pol II: Core component of TFIID for mRNA transcription
- Pol III: Required for tRNA, 5S rRNA, and U6 snRNA transcription
In Pol II transcription, TBP is the core of TFIID:
- TBP binds to the TATA box at -25 to -30
- TAFs (TBP-associated factors) provide promoter recognition
- TFIID nucleates pre-initiation complex assembly
- CAG repeat expansion: Causes SCA17 (polyglutamine disease)
- TBP dysfunction: Leads to transcriptional dysregulation
- Clinical features: Ataxia, dementia, psychiatric symptoms
- TBP inclusions: Found in motor neurons of ALS patients
- Transcriptional disruption: Altered gene expression patterns
- Proteinopathy: TBP aggregation in disease
- Mutant huntingtin: Interacts with TBP and transcription factors
- Transcriptional repression: Reduced expression of neuronal genes
- Epigenetic changes: Histone modifications
- Phosphorylation: Affects transcription factor interactions
- Acetylation: Regulates DNA binding activity
- Ubiquitination: Degradation and quality control
- SUMOylation: Alters protein interactions
- In vitro transcription assays: Functional studies
- ChIP-seq: Genome-wide binding analysis
- EMSA: DNA binding kinetics
- CRISPR screening: Transcription factor dependencies
The study of Tbp Protein Tata Box Binding Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Wassarman DA, Sauer F (2001) TBP: A transcription factor. J Cell Sci 114:689-691. PMID:11171366
- Nikolov DB, Burley SK (1997) RNA polymerase II transcription initiation. Proc Natl Acad Sci USA 94:15-22. PMID:9089566
- Kooper J, et al. (2009) TBP in neurodegeneration. J Mol Neurosci 39:185-195. PMID:19459146
- Friedman MJ, et al. (2007) Polyglutamine disease. Neurology 68:1707-1714. PMID:17495034
- Shimohata T, et al. (2000) Expanded polyglutamine stretches interact with TBP. Nat Genet 26:29-36. PMID:10973244
- Lieberoth A, et al. (2003) SCA17 and transcriptional dysfunction. Brain Res Bull 61:229-237. PMID:12948649
- Liu Y, et al. (2015) TBP modifications in disease. Mol Neurobiol 52:1685-1695. PMID:25394218
- Watson JD, et al. (2013) Molecular Biology of the Gene. Cold Spring Harbor. ISBN: 978-0134988191
[1] Lee TI, Young RA. Transcription of eukaryotic protein-coding genes. Annu Rev Genet. 2000;34:77-137.
[2] Lu T, et al. Gene expression and regulation in AD. Neurobiol Aging. 2004;25(6):711-722.
[3] Shimohata T, et al. TBP in Huntington's disease. Nat Neurosci. 2000;3(12):1224-1227.